Comparing Predictive Oncology (NASDAQ:AGPU) and TransEnterix (OTCMKTS:TRXDW)

Predictive Oncology (NASDAQ:AGPU) and TransEnterix (OTCMKTS:TRXDW) are both small-cap manufacturing companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability and risk.

Institutional & Insider Ownership

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 8.2% of TransEnterix shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by company insiders. Comparatively, 3.1% of TransEnterix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Predictive Oncology and TransEnterix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	N/A	-235.55%
TransEnterix	-2,149.15%	-83.74%	-64.94%

Valuation & Earnings

This table compares Predictive Oncology and TransEnterix”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.62 million	3.10	-$12.66 million	($13.50)	-0.11
TransEnterix	$8.53 million	2.51	-$154.20 million	($4.22)	-0.04

Predictive Oncology has higher earnings, but lower revenue than TransEnterix. Predictive Oncology is trading at a lower price-to-earnings ratio than TransEnterix, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Predictive Oncology has a beta of 1.4, meaning that its share price is 40% more volatile than the S&P 500. Comparatively, TransEnterix has a beta of 2.56, meaning that its share price is 156% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Predictive Oncology and TransEnterix, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1	0	0	0	1.00
TransEnterix	0	0	0	0	0.00

Summary

TransEnterix beats Predictive Oncology on 7 of the 12 factors compared between the two stocks.

About Predictive Oncology

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

About TransEnterix

TransEnterix, Inc., a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe. It also develops SurgiBot System, a single-port system robotically enhanced laparoscopic surgical platform.. TransEnterix, Inc. is headquartered in Morrisville, North Carolina.